nach oben

Current Cardiovascular Imaging Reports

Erschienen in:

01.05.2014 | Molecular Imaging (G Strijkers, Section Editor)

The Use of Superparamagnetic Iron Oxide Nanoparticles to Assess Cardiac Inflammation

verfasst von: Colin G. Stirrat, David E. Newby, Jennifer M. J. Robson, Maurits A. Jansen

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Superparamagnetic iron oxide-based contrast agents enhance and complement in vivo magnetic resonance imaging (MRI) by shortening T2 and T2* relaxation times. They are able to highlight areas of cellular inflammation, being detected and engulfed by cells of the reticuloendothelial system, and can be targeted to specific cellular processes or subtypes using antibody or ligand labeling. These agents have been used preclinically for the assessment of cardiac transplant rejection, cardiomyocyte apoptosis, myocardial infarction, myocarditis, and stem and endothelial cell imaging, with clinical applications now emerging. We here review recent studies using iron oxide particles to image cardiac inflammation, and highlight the potential of these agents for future clinical and research applications.

Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914–31.PubMedCrossRef

Wang Y-XJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319–31.PubMedCrossRef

Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011;1:35–40.PubMedCentralPubMed

Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology. 2002;223:432–8.PubMedCrossRef

Mandeville JB, Moore J, Chesler DA, Garrido L, Weissleder R, Weisskoff RM. Dynamic liver imaging with iron oxide agents: effects of size and biodistribution on contrast. Magn Reson Med. 1997;37:885–90.PubMedCrossRef

Hahn PF, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology. 1990;175:695–700.PubMed

Saini S, Stark DD, Wittenberg J, Brady TJ, Ferrucci JT. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology. 1987;162:211–6.PubMed

Rogers JM, Lewis J, Josephson L. Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide, AMI-227. Magn Reson Imaging. 1994;12:1161–5.PubMedCrossRef

Zimmer C, Weissleder R, O'Connor D, LaPointe L, Brady TJ, Enochs WS. Cerebral iron oxide distribution: in vivo mapping with MR imaging. Radiology. 1995;196:521–7.PubMed

10.

Canet E, Revel D, Forrat R, Baldy-Porcher C, de Lorgeril M, Sebbag L, et al. Superparamagnetic iron oxide particles and positive enhancement for myocardial perfusion studies assessed by subsecond T1-weighted MRI. Magn Reson Imaging. 1993;11:1139–45.PubMedCrossRef

11.

Trillaud H, Degrèze P, Mesplède Y, Douws C, Palussière J, Grenier N. Evaluation of experimentally induced renal hypoperfusion using iron oxide particles and fast magnetic resonance imaging. Acad Radiol. 1995;2:293–9.PubMedCrossRef

12.

McAteer MA, Akhtar AM, von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis. 2010;209:18–27.PubMedCentralPubMedCrossRef

13.

Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol. 2002;37:167–77.PubMedCrossRef

14.

Taylor AM, Panting JR, Keegan J, Gatehouse PD, Amin D, Jhooti P, et al. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging. 1999;9:220–7.PubMedCrossRef

15.

Lind K, Kresse M, Debus NP, Müller RH. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography: comparison of physicochemical properties and the in vivo behaviour. J Drug Target. 2002;10:221–30.PubMedCrossRef

16.

Clément O, Siauve N, Cuénod CA, Frija G. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top Magn Reson Imaging. 1998;9:167–82.PubMedCrossRef

17.

Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee J-M, Jacobs PM, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;41:313–24.PubMedCrossRef

18.

Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TCC. Temporal and noninvasive monitoring of inflammatory—cell infiltration to myocardial infarction sites using micrometer—sized iron oxide particles. Magn Reson Med. 2010;63:33–40.PubMed

19.

Ye Q, Wu YL, Foley LM, Hitchens TK, Eytan DF, Shirwan H, et al. Longitudinal tracking of recipient macrophages in a rat chronic cardiac allograft rejection model with noninvasive magnetic resonance imaging using micrometer-sized paramagnetic iron oxide particles. Circulation. 2008;118:149–56.PubMedCentralPubMedCrossRef

20.

Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjørnerud A, Fayad ZA, et al. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Invest Radiol. 2006;41:560–71.PubMedCrossRef

21.

Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med. 2006;55:242–9.PubMedCrossRef

22.

Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci U S A. 2004;101:10901–6.PubMedCentralPubMedCrossRef

23.

Hertz MI, Aurora P, Christie JD, Dobbels F, Edwards LB, Kirk R, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2009 Annual Reports. J Heart Lung Transplant. 2009;28:989–92.PubMedCrossRef

24.

Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–20.PubMedCrossRef

25.

Kanno S, Wu Y-JL, Lee PC, Dodd SJ, Williams M, Griffith BP, et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation. 2001;104:934–8.PubMedCrossRef

26.

Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK, Ho C. Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2:731–41.PubMedCentralPubMedCrossRef

27.•

Guo Y, Chen W, Wang W, Shen J, Guo R, Gong F, et al. Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart transplantation model using a t-cell-targeted theranostic nanosystem. ACS Nano. 2012;121204131551005. Novel “theranostic” nanosystem allowing diagnosis and treatment (via gene therapy) of allogeneic cardiac transplantation rejection in rats.

28.

Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347–52. doi:10.1038/nm1101-1241 [Pub online: Nov 1, 2001].PubMedCrossRef

29.

Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, et al. A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med. 2011;66:1152–62.PubMedCentralPubMedCrossRef

30.

Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002;9 Suppl 2:S304–6.PubMedCrossRef

31.

Schellenberger EA, Högemann D, Josephson L, Weissleder R. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Acad Radiol. 2002;9 Suppl 2:S310–1.PubMedCrossRef

32.

Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto—optical nanoparticle. Magn Reson Med. 2005;54:718–24.PubMedCrossRef

33.

Sosnovik DE, Garanger E, Aikawa E, Nahrendorf M, Figuiredo J-L, Dai G, et al. Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo potential for midmyocardial salvage in acute ischemia. Circ Cardiovasc Imaging. 2009;2:460–7.PubMedCentralPubMedCrossRef

34.

Yang Y, Liu J, Yang Y, Cho SH, Hu TCC. Assessment of cell infiltration in myocardial infarction: a dose-dependent study using micrometer-sized iron oxide particles. Magn Reson Med. 2011;66:1353–61.PubMedCrossRef

35.••

Alam SR, Shah ASV, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5:559–65. First human studies evaluating uptake of iron nanoparticles after myocardial infarction.PubMedCrossRef

36.••

Yilmaz A, Dengler MA, van der Kuip H, Yildiz H, Rosch S, Klumpp S, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur Heart J. 2013;34:462–75. First human studies evaluating uptake of iron nanoparticles after myocardial infarction.PubMedCrossRef

37.

Grieve SM, Lønborg J, Mazhar J, Tan TC, Ho E, Liu C-C, et al. Cardiac magnetic resonance imaging of rapid VCAM-1 up-regulation in myocardial ischemia–reperfusion injury. Eur Biophys J. 2012;42:61–70.PubMedCrossRef

38.

Ruparelia N, Digby JE, Jefferson A, Medway DJ, Neubauer S, Lygate CA, et al. Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. Inflamm Res. 2013;62:515–25.PubMedCentralPubMedCrossRef

39.

Moon H, Park HE, Kang J, Lee H, Cheong C, Lim YT, et al. Noninvasive assessment of myocardial inflammation by cardiovascular magnetic resonance in a rat model of experimental autoimmune myocarditis. Circulation. 2012;125:2603–12.PubMedCrossRef

40.

Kraitchman DL. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation. 2003;107:2290–3.PubMedCrossRef

41.

Lu M, Zhao S, Liu Q, Jiang S, Song P, Qian H, et al. Transplantation with autologous mesenchymal stem cells after acute myocardial infarction evaluated by magnetic resonance imaging: an experimental study. J Thorac Imaging. 2012;27:125–35.PubMedCrossRef

42.•

Chung J, Kee K, Barral JK, Dash R, Kosuge H, Wang X, et al. In vivo molecular MRI of cell survival and teratoma formation following embryonic stem cell transplantation into the injured murine myocardium. Magn Reson Med. 2011;66:1374–81. Imaging of proliferation and teratoma formation after embryonic stem cell transplantation. A reporter gene expressing antigen on the surface of stem cells allowed quantification of viability and proliferation of stem cells whilst monitoring for teratoma formation.PubMedCentralPubMedCrossRef

43.

Dall’Armellina E, Lygate CA, Mcateer M. Ex vivo and in vivo MR imaging of ischemia reperfusion injury in mouse hearts using microparticles of iron oxide targeting VCAM-1. Proceedings of the 18th Annual Meeting ISMRM, Stockholm, Sweden, 2010;3637.

44.

Gabrielsen A, Lawler PR, Yongzhong W, Steinbrüchel D, Blagoja D, Paulsson-Berne G, et al. Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol. 2007;42:870–83.PubMedCrossRef

45.

Heesakkers RAM, Jager GJ, Hövels AM, de Hoop B, van den Bosch HCM, Raat F, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology. 2009;251:408–14.PubMedCrossRef

Titel: The Use of Superparamagnetic Iron Oxide Nanoparticles to Assess Cardiac Inflammation
verfasst von: Colin G. Stirrat
David E. Newby
Jennifer M. J. Robson
Maurits A. Jansen
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 5/2014
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-014-9263-3

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Use of Superparamagnetic Iron Oxide Nanoparticles to Assess Cardiac Inflammation

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Cardiovascular Magnetic Resonance Imaging of Myocardial Interstitial Expansion in Hypertrophic Cardiomyopathy

Risk Stratification with Cardiac Rubidium-82 Positron Emission Tomography

Cardiac Stem Cell Imaging by SPECT and PET

Improved Prediction of Major Cardiac Events by Gated Myocardial Perfusion Imaging

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie